Glycobia, Inc.
Glycoengineered bacterial outer membrane vesicles (OMVs) displaying tumor-associated carbohydrate antigens for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- Ithaca, NY
- Founded
- 2008
- Latest Form D
- $500K, Oct 2010
- Total capital
- $3.9M
- Federal grants
- $3.4M
- 6 awards · 2015–2019
- Rank in peer group#291 of 514
- Private capital raised
- $500K
- 1 Form D · last Oct 2010
- 193 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 8 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Novel strategy to generate glycan-specific antibodies for cancer immunotherapy$300K
- Federal grantHealth and Human S · Phase I · N glycan specific antibodies for advancing glycobiology research$150K
- Federal grantHealth and Human S · Phase I · N-glycan specific antibodies for advancing glycobiology research$150K
- Federal grantHealth and Human S · Phase II · Glycoconjugate therapeutic peptides for improved treatment of human diseases$766K
- Federal grantHealth and Human S · Phase II · Engineering Escherichia coli for sialylation of therapeutic proteins$595K
- Federal grantHealth and Human S · Phase II · Glycoconjugate therapeutic peptides for improved treatment of human diseases$1.4M
- Private capital raisedForm D · SEC · 1st filing$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#81 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam FisherDirectorNamed in SEC Form D filings
- Chang HongExecutive Officer, DirectorNamed in SEC Form D filings
- Matthew DeLisaExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 8- PendingCompositions And Methods For The Expression Of Eukaryotic Oligosaccharides On Bacterial Outer Membrane VesiclesUSPTOApplication 16302938
- PendingOligosaccharide Compositions, Glycoproteins And Methods To Produce The Same In ProkaryotesUSPTOApplication 14210559
- PendingPolysialic Acid, Blood Group Antigens And Glycoprotein Expression In ProkaryotesUSPTOApplication 14214702
Show all 8 patent records
- Compositions And Methods For The Expression Of Eukaryotic Oligosaccharides On Bacterial Outer Membrane VesiclesMay 16, 2019 · Application 16302938Pending
- Oligosaccharide Compositions, Glycoproteins And Methods To Produce The Same In ProkaryotesSep 18, 2014 · Application 14210559Pending
- Polysialic Acid, Blood Group Antigens And Glycoprotein Expression In ProkaryotesSep 18, 2014 · Application 14214702Pending
- Oligosaccharide Compositions, Glycoproteins And Methods To Produce The Same In ProkaryotesApplication PCTUS2014026990Pending
- Engineered OligosaccharyltransferasesApplication PCTUS2015044395Pending
- Engineered OligosaccharyltransferasesApplication 15502781Pending
- Compositions And Methods For The Expression Of Eukaryotic Oligosaccharides On Bacterial Outer Membrane VesiclesApplication PCTUS2017033156Pending
- Polysialic Acid, Blood Group Antigens And Glycoprotein ExpressionApplication PCTUS2014029897Pending
Recent research by its founders
- Data from Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody–Drug Conjugate20230 cites
- Supplementary Information from Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody–Drug Conjugate20230 cites
- Facilitating practices to support children's self-regulation in classrooms: a scoping review protocol20211 cites
Related companies, and why
- CELLOLOGI, LLCSimilar federal contract value in Biotech · null in contracts
- MIRNATECH INTERNATIONAL, INC.Similar federal contract value in Biotech · null in contracts
- Curve TherapeuticsSimilar federal contract value in Biotech · null in contracts
- AXENT BIOSCIENCES INC.Similar federal contract value in Biotech · null in contracts
- FORMATION VENTURE ENGINEERING FOUNDRY INCSimilar federal contract value in Biotech · null in contracts
- ProteoPrinceps, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .